At a glance
ClinicalIndex Comparison RecordPhase 2Active· 60 enrolled
Drug / intervention
Cannabidiol +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-blind Phase II Study of a Single Dose of Cannabidiol (CBD) for Acute Anticipatory Anxiety in Advanced Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Cannabidiol and Placebo for Advanced Breast Cancer and 2 related conditions. Active but no longer recruiting, targeting 60 participants across 1 site.
Detailed Summary
This research study is investigating use of a single dose of cannabidiol (CBD) to help manage anticipatory anxiety in participants with advanced breast cancer poised to undergo computed tomography (CT) or positron emission tomography (PET) to assess tumor burden. The name of the study drug(s) are: \- Cannabidiol (CBD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Breast Cancer, Anxiety, CBD
CountriesUnited States
CollaboratorsHans and Mavis Lopater Foundation
Timeline
Phase 2Active
2021202220232024202520262027
First PostedJul 2020
Enrollment StartJan 2022
Primary CompletionMar 2023
TodayJul 2026
Study CompletionDec 2026
First PostedJul 22, 2020
Enrollment StartJan 19, 2022
Primary CompletionMar 1, 2023
Study CompletionDec 1, 2026
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 5.9 years ago
Interventions
Cannabidioldrug
Liquid taken orally
Placeboother
Liquid taken orally